Q-omics provides the consensus-scored RPL9P5 profile across patient tissues and cancer cell-line models. RPL9P5 expression is associated with patient survival in 15 of 34 cancer types, with the highest sampling consensus in LIHC. Among the 18 cancer types available for tumor–normal comparison, RPL9P5 is differentially expressed in 4, with the highest sampling consensus in LIHC. Additionally, RPL9P5 RNA expression shows 6,183 significant pathway-activity associations, with the highest sampling consensus in STAD. Together, these results highlight LIHC, and STAD as cancer lineages where RPL9P5 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RPL9P5 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RPL9P5 survival associations across molecular data types. RPL9P5 RNA expression shows survival associations in the most cancer types (15). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RPL9P5 RNA expression–survival associations across cancer types. High RPL9P5 expression shows unfavorable associations in LIHC, KIRC, LGG, BLCA, MESO and LUSC. The LIHC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .004). Together, the overview and detailed table identify LIHC as the clearest survival context for RPL9P5 RNA expression.
This table summarizes RPL9P5 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 4. The strongest signals are observed in LIHC for RNA.
This table ranks reproducible tumor–normal expression differences for RPL9P5. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RPL9P5 shows lower tumor expression in KIRC and higher tumor expression in LIHC, BLCA and BRCA. The LIHC box plot shows higher RPL9P5 RNA expression in tumor versus normal tissue (log2 FC = +0.070, t-test p = .001).
This table shows molecular features associated with RPL9P5 in patient tissues and cancer cell lines. In patient samples, RPL9P5 shows the broadest associations at the RNA and protein expression levels, with STAD recurring as the lineage with the largest associated feature set.
